Supernus Pharmaceuticals, Inc. (SUPN)
- Previous Close
30.77 - Open
30.85 - Bid 30.70 x 100
- Ask 30.80 x 100
- Day's Range
30.63 - 31.40 - 52 Week Range
21.99 - 35.44 - Volume
294,058 - Avg. Volume
440,606 - Market Cap (intraday)
1.694B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
341.67 - EPS (TTM)
0.09 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.25
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
www.supernus.com652
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SUPN
View MorePerformance Overview: SUPN
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUPN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUPN
View MoreValuation Measures
Market Cap
1.69B
Enterprise Value
1.39B
Trailing P/E
341.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.67
Price/Book (mrq)
1.77
Enterprise Value/Revenue
2.20
Enterprise Value/EBITDA
11.33
Financial Highlights
Profitability and Income Statement
Profit Margin
0.83%
Return on Assets (ttm)
1.95%
Return on Equity (ttm)
0.56%
Revenue (ttm)
630.16M
Net Income Avi to Common (ttm)
5.24M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
347.19M
Total Debt/Equity (mrq)
4.18%
Levered Free Cash Flow (ttm)
219.26M